A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)
Clinical trial NCT03093480 · COMPLETED
Trial details
- NCT number
- NCT03093480
- Sponsor
- Bioverativ, a Sanofi company
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-08
- Primary completion
- 2020-05-04
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.